Identification

Name
Moclobemide
Accession Number
DB01171  (APRD00603)
Type
Small Molecule
Groups
Approved
Description

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.

Structure
Thumb
Synonyms
  • 4-Chlor-N-(2-morpholinoethyl)benzamid
  • 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
  • 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
  • Aurorix
  • Moclaime
  • Moclamide
  • Moclamine
  • Moclobemid
  • Moclobemida
  • Moclobemide
  • Moclobemidum
  • p-Chloro-N-(2-morpholinoethyl)benzamide
External IDs
RO 11-1163/000
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-moclobemide Tablets 150mgTablet150 mgOralDominion Pharmacal2001-02-152016-10-26Canada
Dom-moclobemide Tablets 300mgTablet300 mgOralDominion Pharmacal2001-02-152016-10-26Canada
ManerixTablet300 mgOralValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
ManerixTablet150 mgOralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Manerix Tab 100mgTablet100 mgOralHoffmann La Roche1992-12-311997-12-04Canada
Moclobemide-100Tablet100 mgOralPro Doc Limitee1998-06-022009-07-23Canada
Moclobemide-150Tablet150 mgOralPro Doc Limitee1998-06-022009-07-23Canada
Nu-moclobemideTablet100 mgOralNu Pharm Inc1998-07-292012-09-04Canada
Nu-moclobemideTablet150 mgOralNu Pharm Inc1998-07-282012-09-04Canada
PMS-moclobemideTablet300 mgOralPharmascience Inc2001-01-08Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-moclobemideTablet100 mgOralApotex Corporation1997-09-18Not applicableCanada
Apo-moclobemideTablet300 mgOralApotex Corporation1999-07-14Not applicableCanada
Apo-moclobemideTablet150 mgOralApotex Corporation1997-09-18Not applicableCanada
International/Other Brands
Aurorix
Categories
UNII
PJ0Y7AZB63
CAS number
71320-77-9
Weight
Average: 268.739
Monoisotopic: 268.097855505
Chemical Formula
C13H17ClN2O2
InChI Key
YHXISWVBGDMDLQ-UHFFFAOYSA-N
InChI
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
IUPAC Name
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
SMILES
ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Pharmacodynamics

Moclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.

Mechanism of action

The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption

Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration.

Volume of distribution
Not Available
Protein binding

Approximately 50% (primarily to albumin)

Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.

Route of elimination
Not Available
Half life

1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

Clearance
Not Available
Toxicity

LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineMoclobemide may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineMoclobemide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMoclobemide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Moclobemide.Experimental
AbirateroneThe serum concentration of Moclobemide can be increased when it is combined with Abiraterone.Approved
AcarboseMoclobemide may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololMoclobemide may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Moclobemide.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acetophenazine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Moclobemide.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Moclobemide.Experimental
AlbiglutideMoclobemide may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Moclobemide.Approved, Illicit
AliskirenMoclobemide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Moclobemide.Approved, Investigational
AlogliptinMoclobemide may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Moclobemide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Moclobemide.Illicit
AlprenololMoclobemide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Moclobemide.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Moclobemide.Approved, Investigational
AmineptineMoclobemide may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Moclobemide.Approved, Withdrawn
AmiodaroneThe metabolism of Moclobemide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Moclobemide.Approved
AmlodipineMoclobemide may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Moclobemide.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Moclobemide.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Moclobemide.Approved, Illicit
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Moclobemide.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Moclobemide.Approved
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Moclobemide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Apraclonidine.Approved
AprepitantThe metabolism of Moclobemide can be increased when combined with Aprepitant.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Moclobemide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Moclobemide can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Moclobemide can be decreased when combined with Artemether.Approved
AsenapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Asenapine.Approved
AtenololMoclobemide may increase the hypotensive activities of Atenolol.Approved
AtomoxetineMoclobemide may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineMoclobemide may increase the hypertensive activities of Atropine.Approved, Vet Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Moclobemide.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Azaperone.Investigational, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Moclobemide.Approved
BambuterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bambuterol.Approved, Investigational
BenazeprilMoclobemide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMoclobemide may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Moclobemide.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Moclobemide.Approved
BenzphetamineMoclobemide may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilMoclobemide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Moclobemide.Approved
BetaxololThe metabolism of Moclobemide can be decreased when combined with Betaxolol.Approved
BethanidineMoclobemide may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bezafibrate.Approved
BietaserpineMoclobemide may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bifeprunox.Investigational
BimatoprostMoclobemide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololMoclobemide may increase the hypotensive activities of Bisoprolol.Approved
BortezomibThe metabolism of Moclobemide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanMoclobemide may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Moclobemide may increase the hypotensive activities of BQ-123.Investigational
BretyliumMoclobemide may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brimonidine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Moclobemide.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Moclobemide.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Moclobemide.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Moclobemide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Moclobemide.Approved, Investigational
BupranololMoclobemide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide.Approved, Illicit, Investigational, Vet Approved
BupropionMoclobemide may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Moclobemide.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Moclobemide.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Moclobemide.Approved
CadralazineMoclobemide may increase the hypotensive activities of Cadralazine.Experimental
CafedrineMoclobemide may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinMoclobemide may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanMoclobemide may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilMoclobemide may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilMoclobemide may increase the hypotensive activities of Candoxatril.Experimental
CapecitabineThe metabolism of Moclobemide can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilMoclobemide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Moclobemide.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Moclobemide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Moclobemide.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Cariprazine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Moclobemide.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Moclobemide.Withdrawn
CarteololMoclobemide may increase the hypotensive activities of Carteolol.Approved
CarvedilolMoclobemide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Moclobemide can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMoclobemide may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Moclobemide can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Moclobemide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Moclobemide can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideMoclobemide may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineMoclobemide may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Moclobemide can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideMoclobemide may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneMoclobemide may increase the hypotensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Moclobemide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineMoclobemide may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMoclobemide may increase the hypotensive activities of Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Moclobemide.Approved
CimetidineThe metabolism of Moclobemide can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Moclobemide can be decreased when combined with Cinacalcet.Approved
CirazolineMoclobemide may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Moclobemide.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Moclobemide.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Moclobemide.Approved
ClemastineMoclobemide may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobazamThe metabolism of Moclobemide can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Moclobemide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clomipramine.Approved, Vet Approved
ClonidineMoclobemide may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Moclobemide resulting in a loss in efficacy.Approved, Nutraceutical
CloranololMoclobemide may increase the hypotensive activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clothiapine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Moclobemide.Approved, Illicit
ClotrimazoleThe metabolism of Moclobemide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Moclobemide can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Moclobemide can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Moclobemide can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Moclobemide.Approved, Illicit
CrisaboroleThe metabolism of Moclobemide can be decreased when combined with Crisaborole.Approved
CryptenamineMoclobemide may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Moclobemide.Approved
CyclopenthiazideMoclobemide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.Approved, Investigational
CyclosporineThe metabolism of Moclobemide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideMoclobemide may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineMoclobemide may increase the anticholinergic activities of Cyproheptadine.Approved
DabrafenibThe serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinMoclobemide may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Moclobemide.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Moclobemide.Approved, Investigational
DarifenacinThe metabolism of Moclobemide can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Moclobemide can be increased when it is combined with Darunavir.Approved
DebrisoquinMoclobemide may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilMoclobemide may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Moclobemide can be decreased when combined with Delavirdine.Approved
DeserpidineMoclobemide may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Moclobemide.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Desvenlafaxine.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Moclobemide.Approved
DexmethylphenidateMoclobemide may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineMoclobemide may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanMoclobemide may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Moclobemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Moclobemide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Moclobemide.Approved, Investigational
DiazepamThe metabolism of Diazepam can be decreased when combined with Moclobemide.Approved, Illicit, Vet Approved
DiazoxideMoclobemide may increase the hypotensive activities of Diazoxide.Approved
DibenzepinMoclobemide may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Moclobemide.Approved, Vet Approved
diethylnorspermineMoclobemide may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionMoclobemide may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineMoclobemide may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Moclobemide.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Moclobemide.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Moclobemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Moclobemide.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Moclobemide.Approved
DiphenhydramineThe metabolism of Moclobemide can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Moclobemide.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dipivefrin.Approved
DisopyramideMoclobemide may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Moclobemide.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone.Approved, Investigational, Vet Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Moclobemide.Approved
DorzolamideMoclobemide may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Moclobemide can be decreased when combined with Dosulepin.Approved
DoxapramMoclobemide may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Moclobemide.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Moclobemide.Approved
DoxylamineMoclobemide may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Moclobemide.Experimental
DronabinolThe metabolism of Dronabinol can be decreased when combined with Moclobemide.Approved, Illicit
DronedaroneThe metabolism of Moclobemide can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Moclobemide.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droxidopa.Approved, Investigational
DulaglutideMoclobemide may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Moclobemide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Moclobemide.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Moclobemide can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineMoclobemide may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Moclobemide.Approved, Investigational
EliglustatThe metabolism of Moclobemide can be decreased when combined with Eliglustat.Approved
EmpagliflozinMoclobemide may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilMoclobemide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMoclobemide may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Moclobemide.Approved
EndralazineMoclobemide may increase the hypotensive activities of Endralazine.Experimental
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Moclobemide.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Moclobemide.Approved, Investigational
EpanololMoclobemide may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineMoclobemide may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolMoclobemide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanMoclobemide may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Moclobemide.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Moclobemide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Moclobemide can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineMoclobemide may increase the serotonergic activities of Esmirtazapine.Investigational
EsomeprazoleThe metabolism of Moclobemide can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Moclobemide.Approved, Investigational, Vet Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Moclobemide.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Moclobemide.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Moclobemide.Approved
EtoperidoneMoclobemide may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Moclobemide.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Moclobemide.Approved
ExenatideMoclobemide may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FamotidineThe metabolism of Famotidine can be decreased when combined with Moclobemide.Approved
FelodipineMoclobemide may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamMoclobemide may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Moclobemide.Approved, Illicit, Investigational, Vet Approved
Ferulic acidMoclobemide may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Moclobemide.Approved
FloxuridineThe metabolism of Moclobemide can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Moclobemide can be decreased when combined with Fluconazole.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Moclobemide.Approved, Illicit
FluorouracilThe metabolism of Moclobemide can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Moclobemide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Moclobemide.Approved
FluvastatinThe metabolism of Moclobemide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Moclobemide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Moclobemide.Approved, Investigational
FosinoprilMoclobemide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Moclobemide can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Moclobemide.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide.Approved, Investigational, Vet Approved
GemfibrozilThe metabolism of Moclobemide can be decreased when combined with Gemfibrozil.Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Moclobemide.Experimental
GliclazideMoclobemide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMoclobemide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMoclobemide may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Moclobemide.Approved
GlyburideMoclobemide may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Moclobemide.Approved, Investigational
GuanabenzMoclobemide may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelMoclobemide may increase the hypotensive activities of Guanadrel.Approved
GuanazodineMoclobemide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMoclobemide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Moclobemide.Approved, Investigational
GuanoclorMoclobemide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMoclobemide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMoclobemide may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Moclobemide can be decreased when combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Moclobemide.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Moclobemide.Approved, Illicit, Investigational
HexamethoniumMoclobemide may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Moclobemide.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Moclobemide.Experimental
HydralazineMoclobemide may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideMoclobemide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideMoclobemide may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineMoclobemide may increase the hypertensive activities of Hydroxyamphetamine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Moclobemide.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Moclobemide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Iloperidone.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Moclobemide.Approved
ImidaprilMoclobemide may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Moclobemide.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Indacaterol.Approved
IndalpineMoclobemide may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideMoclobemide may increase the hypotensive activities of Indapamide.Approved
IndenololMoclobemide may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Moclobemide can be decreased when combined with Indinavir.Approved
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Moclobemide.Approved, Investigational
IndoraminMoclobemide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartMoclobemide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMoclobemide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMoclobemide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMoclobemide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMoclobemide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMoclobemide may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Moclobemide.Approved
IprindoleMoclobemide may increase the serotonergic activities of Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Moclobemide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Moclobemide.Withdrawn
IrbesartanThe metabolism of Moclobemide can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moclobemide.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isometheptene.Approved
IsoniazidThe metabolism of Moclobemide can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isoprenaline.Approved
IsradipineMoclobemide may increase the hypotensive activities of Isradipine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Moclobemide.Approved
KetanserinMoclobemide may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Moclobemide.Approved, Investigational
KetoconazoleThe metabolism of Moclobemide can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Moclobemide.Approved, Nutraceutical, Withdrawn
LabetalolMoclobemide may increase the hypotensive activities of Labetalol.Approved
LacidipineMoclobemide may increase the hypotensive activities of Lacidipine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Moclobemide.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Moclobemide.Approved, Investigational
LatanoprostMoclobemide may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Moclobemide can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineMoclobemide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Moclobemide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Moclobemide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Moclobemide is combined with Levomilnacipran.Approved
LevonordefrinMoclobemide may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Moclobemide.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Moclobemide is combined with Linezolid.Approved, Investigational
LinsidomineMoclobemide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideMoclobemide may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineMoclobemide may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilMoclobemide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Moclobemide.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lithium.Approved
LobeglitazoneThe metabolism of Moclobemide can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Moclobemide.Illicit
LofepramineMoclobemide may increase the serotonergic activities of Lofepramine.Experimental
LofexidineMoclobemide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Moclobemide can be decreased when combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lorcaserin.Approved
LosartanThe metabolism of Moclobemide can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Moclobemide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Moclobemide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Moclobemide can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Moclobemide can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Moclobemide.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Moclobemide.Approved
ManidipineMoclobemide may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Moclobemide.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Moclobemide.Withdrawn
MecamylamineMoclobemide may increase the hypotensive activities of Mecamylamine.Approved
MecaserminMoclobemide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelatoninThe metabolism of Melatonin can be decreased when combined with Moclobemide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Melperone.Approved, Investigational
MephedroneMoclobemide may increase the hypertensive activities of Mephedrone.Investigational
MephentermineMoclobemide may increase the hypertensive activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Moclobemide.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Moclobemide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Moclobemide.Experimental
MequitazineMoclobemide may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mesoridazine.Approved, Investigational
MetaraminolMoclobemide may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminMoclobemide may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Moclobemide.Approved, Illicit
MethamphetamineMoclobemide may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineMoclobemide may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Moclobemide can be decreased when combined with Methotrimeprazine.Approved
MethoxamineMoclobemide may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Moclobemide.Experimental
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Moclobemide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Moclobemide.Experimental
Methylene blueMoclobemide may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateMoclobemide may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Moclobemide.Approved
MetipranololMoclobemide may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.Approved, Investigational
MetolazoneMoclobemide may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Moclobemide.Approved, Investigational
MetyrosineMoclobemide may increase the hypotensive activities of Metyrosine.Approved
MianserinMoclobemide may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilMoclobemide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineMoclobemide may increase the hypertensive activities of Midodrine.Approved
MidomafetamineMoclobemide may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Moclobemide can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Moclobemide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMoclobemide may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Moclobemide is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Moclobemide.Approved
MinoxidilMoclobemide may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe metabolism of Moclobemide can be decreased when combined with Mirabegron.Approved
MirtazapineMoclobemide may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAMoclobemide may increase the hypertensive activities of MMDA.Experimental, Illicit
ModafinilThe metabolism of Moclobemide can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoclobemide may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mosapramine.Experimental
MoxonidineMoclobemide may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineMoclobemide may increase the hypotensive activities of Muzolimine.Experimental
NadololMoclobemide may increase the hypotensive activities of Nadolol.Approved
NaftopidilMoclobemide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Moclobemide.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Moclobemide.Approved, Investigational
NateglinideMoclobemide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololMoclobemide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Moclobemide.Approved, Withdrawn
NelfinavirThe metabolism of Moclobemide can be decreased when combined with Nelfinavir.Approved
NevirapineThe metabolism of Moclobemide can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Moclobemide.Withdrawn
NicardipineThe metabolism of Moclobemide can be decreased when combined with Nicardipine.Approved
NicorandilMoclobemide may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Moclobemide.Approved
NiguldipineMoclobemide may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Moclobemide can be decreased when combined with Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Moclobemide.Approved
NilvadipineMoclobemide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineMoclobemide may increase the hypotensive activities of Nimodipine.Approved
NisoldipineMoclobemide may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineMoclobemide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideMoclobemide may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineMoclobemide may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Moclobemide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Moclobemide.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Moclobemide.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine.Approved, Investigational
OlmesartanMoclobemide may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olodaterol.Approved
OmapatrilatMoclobemide may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Moclobemide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Moclobemide.Approved
OpipramolMoclobemide may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Moclobemide.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Moclobemide is combined with Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Moclobemide.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Moclobemide.Approved
OxprenololMoclobemide may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Moclobemide.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Oxypertine.Experimental
PaliperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Moclobemide.Approved, Investigational
PanobinostatThe serum concentration of Moclobemide can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Moclobemide can be decreased when combined with Pantoprazole.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Moclobemide.Approved
ParoxetineThe metabolism of Moclobemide can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMoclobemide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Penfluridol.Experimental
PentamidineMoclobemide may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Moclobemide.Approved, Vet Approved
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Moclobemide.Approved, Vet Approved
PentoliniumMoclobemide may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Moclobemide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilMoclobemide may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Moclobemide.Approved
PethidineMoclobemide may increase the serotonergic activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Moclobemide.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Moclobemide.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moclobemide.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Moclobemide.Withdrawn
PhenobarbitalThe metabolism of Moclobemide can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Moclobemide.Experimental
PhenoxybenzamineMoclobemide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Moclobemide.Withdrawn
PhentermineMoclobemide may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineMoclobemide may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineMoclobemide may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Moclobemide can be increased when combined with Phenytoin.Approved, Vet Approved
PholcodinePholcodine may increase the serotonergic activities of Moclobemide.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Moclobemide.Investigational
PimozideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pimozide.Approved
PinacidilMoclobemide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololMoclobemide may increase the hypotensive activities of Pindolol.Approved
PioglitazoneMoclobemide may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pipamperone.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Moclobemide.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Moclobemide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Moclobemide.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Moclobemide.Withdrawn
PizotifenMoclobemide may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorMoclobemide may increase the hypotensive activities of Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Moclobemide.Approved
PolythiazideMoclobemide may increase the hypotensive activities of Polythiazide.Approved
PramlintideMoclobemide may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Moclobemide.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Moclobemide.Approved, Vet Approved
PrazosinMoclobemide may increase the hypotensive activities of Prazosin.Approved
PrimidoneThe metabolism of Moclobemide can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Moclobemide.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Moclobemide.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Moclobemide.Approved
PromazineThe metabolism of Moclobemide can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Moclobemide.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Moclobemide.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Moclobemide.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Moclobemide.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Moclobemide.Investigational
PseudoephedrineMoclobemide may increase the hypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Moclobemide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Moclobemide.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Moclobemide.Approved
QuinaprilMoclobemide may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Moclobemide can be decreased when combined with Quinidine.Approved
QuinineMoclobemide may increase the hypoglycemic activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Moclobemide.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Raclopride.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Moclobemide.Approved, Investigational
RamiprilMoclobemide may increase the hypotensive activities of Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Moclobemide.Approved
RanolazineThe metabolism of Moclobemide can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moclobemide.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Moclobemide.Approved
RemikirenMoclobemide may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride.Approved, Withdrawn
RepaglinideMoclobemide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineMoclobemide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Reserpine.Approved, Investigational
RifampicinThe metabolism of Moclobemide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Moclobemide can be increased when combined with Rifapentine.Approved
RilmenidineMoclobemide may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatMoclobemide may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ritanserin.Investigational
RitobegronMoclobemide may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Moclobemide can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Moclobemide.Approved
RolapitantThe metabolism of Moclobemide can be decreased when combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Moclobemide.Approved, Investigational
RopiniroleThe metabolism of Moclobemide can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneMoclobemide may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Moclobemide.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Moclobemide.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Moclobemide.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salmeterol.Approved
SaprisartanMoclobemide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinMoclobemide may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalThe metabolism of Moclobemide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Moclobemide.Approved, Investigational, Vet Approved
SelexipagMoclobemide may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Moclobemide.Approved
SertindoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Moclobemide.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Moclobemide.Approved, Investigational
SitagliptinMoclobemide may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanMoclobemide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Moclobemide can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilMoclobemide may increase the hypotensive activities of Spirapril.Approved
StiripentolThe metabolism of Moclobemide can be decreased when combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Moclobemide.Approved, Investigational
SulfadiazineThe metabolism of Moclobemide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleMoclobemide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Moclobemide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Moclobemide.Approved, Investigational
SunitinibMoclobemide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololMoclobemide may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Moclobemide.Approved
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Moclobemide.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Moclobemide.Approved
TelmisartanMoclobemide may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Moclobemide.Approved
TemocaprilMoclobemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TeniposideThe metabolism of Teniposide can be decreased when combined with Moclobemide.Approved
TerbinafineThe metabolism of Moclobemide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Terbutaline.Approved
TerlipressinMoclobemide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Moclobemide.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Moclobemide.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Moclobemide.Approved
TetrahydropalmatineMoclobemide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineMoclobemide may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Moclobemide.Approved, Investigational, Withdrawn
TheodrenalineMoclobemide may increase the hypotensive activities of Theodrenaline.Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Moclobemide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Moclobemide.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Tiapride.Approved, Investigational
TiboloneMoclobemide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Moclobemide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Moclobemide can be decreased when combined with Ticlopidine.Approved
TicrynafenMoclobemide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Moclobemide.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Moclobemide.Approved
TipranavirThe metabolism of Moclobemide can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Moclobemide.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Moclobemide.Approved, Investigational
TolazamideMoclobemide may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineMoclobemide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Moclobemide can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moclobemide.Approved, Withdrawn
TolonidineMoclobemide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Moclobemide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Moclobemide.Approved, Investigational
TopiramateThe metabolism of Moclobemide can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Moclobemide can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideMoclobemide may increase the hypotensive activities of Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Moclobemide.Approved, Investigational
TramadolTramadol may increase the neuroexcitatory activities of Moclobemide.Approved, Investigational
TrandolaprilMoclobemide may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Moclobemide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.Approved
TravoprostMoclobemide may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Moclobemide.Approved, Investigational
TreprostinilMoclobemide may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideMoclobemide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinMoclobemide may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Moclobemide.Approved
TrimethaphanMoclobemide may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe metabolism of Moclobemide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Moclobemide.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Moclobemide.Investigational, Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Moclobemide.Approved, Investigational
UnoprostoneMoclobemide may increase the hypotensive activities of Unoprostone.Approved
UrapidilMoclobemide may increase the hypotensive activities of Urapidil.Investigational
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Moclobemide.Approved, Investigational
ValsartanThe metabolism of Moclobemide can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Moclobemide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Moclobemide.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Veralipride.Experimental
VerapamilThe metabolism of Verapamil can be decreased when combined with Moclobemide.Approved
VilanterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Moclobemide.Approved
VincamineMoclobemide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMoclobemide may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Moclobemide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Moclobemide.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Moclobemide.Approved
XipamideMoclobemide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMoclobemide may increase the hypotensive activities of Xylometazoline.Approved
ZafirlukastThe metabolism of Moclobemide can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Moclobemide.Approved
ZimelidineMoclobemide may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Moclobemide can be decreased when combined with Ziprasidone.Approved
ZofenoprilMoclobemide may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Moclobemide.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Moclobemide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Moclobemide can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Food slows absorption a little. Avoid alcohol. Take after meals in order to minimize the risk of interaction with tyramine.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15302
KEGG Drug
D02561
PubChem Compound
4235
PubChem Substance
46504667
ChemSpider
4087
BindingDB
15613
ChEBI
83531
ChEMBL
CHEMBL86304
Therapeutic Targets Database
DAP000576
PharmGKB
PA452615
Wikipedia
Moclobemide
ATC Codes
N06AG02 — Moclobemide
AHFS Codes
  • 28:16.04.12 — Monoamine Oxidase Inhibitors

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAddictions1
2CompletedTreatmentNicotine Dependence1
3CompletedTreatmentClozapine-induced Hypersalivation1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral150 mg
TabletOral300 mg
Prices
Unit descriptionCostUnit
Manerix 300 mg Tablet1.34USD tablet
Apo-Moclobemide 300 mg Tablet0.75USD tablet
Novo-Moclobemide 300 mg Tablet0.75USD tablet
Pms-Moclobemide 300 mg Tablet0.75USD tablet
Manerix 150 mg Tablet0.68USD tablet
Apo-Moclobemide 150 mg Tablet0.38USD tablet
Novo-Moclobemide 150 mg Tablet0.38USD tablet
Pms-Moclobemide 150 mg Tablet0.38USD tablet
Apo-Moclobemide 100 mg Tablet0.26USD tablet
Novo-Moclobemide 100 mg Tablet0.26USD tablet
Nu-Moclobemide 100 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.12 mg/mLALOGPS
logP1.56ALOGPS
logP1.45ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.73ChemAxon
pKa (Strongest Basic)6.02ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity71.93 m3·mol-1ChemAxon
Polarizability28.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9691
Caco-2 permeable-0.5602
P-glycoprotein substrateSubstrate0.6652
P-glycoprotein inhibitor IInhibitor0.6892
P-glycoprotein inhibitor IINon-inhibitor0.8637
Renal organic cation transporterNon-inhibitor0.5691
CYP450 2C9 substrateNon-substrate0.8538
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5723
CYP450 1A2 substrateNon-inhibitor0.9138
CYP450 2C9 inhibitorNon-inhibitor0.8989
CYP450 2D6 inhibitorNon-inhibitor0.8081
CYP450 2C19 inhibitorInhibitor0.8024
CYP450 3A4 inhibitorNon-inhibitor0.9384
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5956
Ames testNon AMES toxic0.6867
CarcinogenicityNon-carcinogens0.8727
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.6098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7135
hERG inhibition (predictor II)Inhibitor0.5646
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-2900000000-c3230d46878446405991
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-3436435ae42cfbae36f0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-ebaa843d45c4c64c1d3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0970000000-ab2fbe8b1feae9ff3141
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e3243f45e1029a4c0e71
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-927950435244f3ac04e4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-6fe640038cbc911e2bae
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-26e37ce9ba0b814b7409
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-07e0ca3dba489a2810ec
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0980000000-70103607e1e68c966be9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-ac7d3f04849dde0da3d2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001r-0900000000-6634fb6b07312ce02ee6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-c43f4a856e6d225766ef
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-1231bd387729155af4ab
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-a885de4ee2be84e3748d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lr-0950000000-2942178c074461702181
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0019-2900000000-bf1e7c693c96e9a69966

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
4-halobenzoic acids and derivatives
Alternative Parents
Benzamides / Benzoyl derivatives / Chlorobenzenes / Morpholines / Aryl chlorides / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives / Oxacyclic compounds / Dialkyl ethers
show 5 more
Substituents
4-halobenzoic acid or derivatives / Benzamide / Benzoyl / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Morpholine / Oxazinane / Amino acid or derivatives
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
benzamides, monochlorobenzenes, morpholines (CHEBI:83531)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16. [PubMed:1705137]
  3. Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 Sep;52(3):450-74. [PubMed:8875133]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Fisar Z, Hroudova J, Raboch J: Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645-56. [PubMed:21200377]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 04, 2017 13:13